AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7975663 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion
Number of subjects: 4
Study 378671 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily Sotalol (80 to 320mg/day)
Number of subjects: 30
Study 378671 — intervention group
Group type: COMPARATOR
Intervention: Twice daily Sotalol (80 to 320mg/day)
Number of subjects: 30
Study 30228034 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.02‐mm‐sized TTs (thermoplastic elastomer)
Number of subjects: 75
Study 30228034 — intervention group
Group type: COMPARATOR
Intervention: 1.14‐mm‐sized TTs (silicone)
Number of subjects: 75
Study 28039187 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial combination therapy with ambrisentan and tadalafil
Number of subjects: 500
Study 26028098 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day levofloxacin-dexlansoprazole based quadruple therapy
Number of subjects: 100
Study 26028098 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day levofloxacin-dexlansoprazole based quadruple therapy
Number of subjects: 100
Study 24382103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Effects on Lipids and Thrombogenic Activity (DELTA) Study
Number of subjects: 103
Study 21955635 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival bevacizumab (1.25 mg/0.1 mL) injected immediately after surgical excision of the pterygium
Number of subjects: 80
Study 21955635 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered in the same way
Number of subjects: 80
Study 18692827 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescent in situ hybridization (FISH) for chromosomes X, Y, 13, 15, 16, 17, 18, 21, and 22
Number of subjects: 62
Study 18692827 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preimplantation aneuploidy testing)
Number of subjects: 62
Study 18692827 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (preimplantation aneuploidy testing)
Number of subjects: 62
Study 17493446 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive control of cardiovascular risk factors (CVRF) protocol
Number of subjects: 184
Study 17493446 — intervention group
Group type: COMPARATOR
Intervention: Normal practice (control group)
Number of subjects: 184
Study 14760477 — intervention group
Group type: EXPERIMENTAL
Intervention: AneuRx device
Number of subjects: 41
Study 14760477 — intervention group
Group type: EXPERIMENTAL
Intervention: Zenith device
Number of subjects: 41
Study 11427642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS, n=35)
Number of subjects: 75
Study 11427642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF, n=40)
Number of subjects: 75
Study 11427642 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive recipients, n=10)
Number of subjects: 75
Study 11427642 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (NIF)
Number of subjects: 75
Study 11427642 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (LIS)
Number of subjects: 75
Study 11427642 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive recipients)
Number of subjects: 75
Study 9728834 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural lidocaine plus epidural fentanyl
Number of subjects: 14
Study 9728834 — intervention group
Group type: COMPARATOR
Intervention: Epidural lidocaine alone
Number of subjects: 14
Study 7750682 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (600 mg/day)
Number of subjects: 75
Study 7750682 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (60 mg/day)
Number of subjects: 75
Study 3386845 — intervention group
Group type: EXPERIMENTAL
Intervention: Copolymer 1 (COP-1) - daily intramuscular doses of 20 mg (2 patients) and twice daily subcutaneous doses of 15 mg (3 patients)
Number of subjects: 5
Study 31857264 — intervention group
Group type: COMPARATOR
Intervention: ICD-9-CM codes alone
Number of subjects: 3907
Study 31857264 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP in combination with ICD-9-CM codes
Number of subjects: 3907
Study 31857264 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP
Number of subjects: 3907
Study 31512258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study 31512258 — intervention group
Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0
Study 31512258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib in genomic high-risk population
Number of subjects: 0
Study 28684258 — intervention group
Group type: EXPERIMENTAL
Intervention: Real anodal tDCS
Number of subjects: 40
Study 28684258 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 40
Study 26557471 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-session in-person culturally-based ¡Cocinar para su salud! dietary modification program
Number of subjects: 102
Study 26557471 — intervention group
Group type: COMPARATOR
Intervention: Written materials (control arm)
Number of subjects: 102
Study 24010917 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent pneumococcal-Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
Number of subjects: 206
Study 24010917 — intervention group
Group type: COMPARATOR
Intervention: Control meningococcal (ACYW135) conjugate vaccine
Number of subjects: 206
Study 21534244 — intervention group
Group type: EXPERIMENTAL
Intervention: HD+HP (hemodialysis with hemoperfusion) once a week
Number of subjects: 100
Study 21534244 — intervention group
Group type: COMPARATOR
Intervention: HD (hemodialysis) alone 3 times a week
Number of subjects: 100
Study 19798013 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment approach (N=18) using 30 mL of 1.5% mepivacaine
Number of subjects: 36
Study 19798013 — intervention group
Group type: COMPARATOR
Intervention: Anterior 3‐in‐1 femoral nerve block (N=18)
Number of subjects: 36
Study 19798013 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior psoas compartment approach
Number of subjects: 36
Study 19798013 — intervention group
Group type: COMPARATOR
Intervention: Anterior 3‐in‐1 femoral nerve block
Number of subjects: 36
Study 16548084 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES therapy
Number of subjects: 26
Study 16548084 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 12923651 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato products (raw, sauce, and paste) providing approximately eight mg lycopene/day for three weeks (T21)
Number of subjects: 12
Study 12923651 — intervention group
Group type: COMPARATOR
Intervention: Carotenoid-poor diet (T0)
Number of subjects: 12
Study 11232753 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 1658
Study 11232753 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (5-20 mg/day)
Number of subjects: 1658
Study 9931882 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant intraoperative radiotherapy (IORT)
Number of subjects: 0
Study 9931882 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 7799586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular quantum hemotherapy
Number of subjects: 0
Study 7799586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined methods of quantum hemotherapy
Number of subjects: 0
Study 7799586 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 2623032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral d-amphetamine in fasting state (FAST/DRUG)
Number of subjects: 12
Study 2623032 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral d-amphetamine in fed state (FED/DRUG)
Number of subjects: 12
Study 2623032 — intervention group
Group type: COMPARATOR
Intervention: Placebo in fasting state (FAST/PLACEBO)
Number of subjects: 12
Study 2623032 — intervention group
Group type: COMPARATOR
Intervention: Placebo in fed state (FED/PLACEBO)
Number of subjects: 12
Study 31769371 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent high PTSD symptoms
Number of subjects: 51965
Study 31769371 — intervention group
Group type: EXPERIMENTAL
Intervention: New-onset high PTSD symptoms
Number of subjects: 51965
Study 31769371 — intervention group
Group type: COMPARATOR
Intervention: No trauma exposure
Number of subjects: 51965
Study 31056427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CAL02 (4 mg/kg)
Number of subjects: 19
Study 31056427 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose CAL02 (16 mg/kg)
Number of subjects: 19
Study 31056427 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 19
Study 31056427 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CAL02 groups
Number of subjects: 19
Study 31056427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 28205117 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular ultrasound-guided infraclavicular block
Number of subjects: 90
Study 28205117 — intervention group
Group type: COMPARATOR
Intervention: Paracoracoid ultrasound-guided infraclavicular block
Number of subjects: 90
Study 25840550 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte telomere length (LTL)
Number of subjects: 353
Study 24005546 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect alcohol use biomarkers (GGT, AST)
Number of subjects: 30
Study 24005546 — intervention group
Group type: EXPERIMENTAL
Intervention: GGT
Number of subjects: 30
Study 24005546 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct alcohol use biomarkers
Number of subjects: 30
Study 21393255 — intervention group
Group type: EXPERIMENTAL
Intervention: L-BLP25 liposome vaccine (1000 μg subcutaneously)
Number of subjects: 6
Study 21393255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (300 mg/m2 i.v. single dose)
Number of subjects: 6
Study 19624964 — intervention group
Group type: COMPARATOR
Intervention: Passive strategy (Group I)
Number of subjects: 22
Study 19624964 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative educative strategy (Group II)
Number of subjects: 22
Study 18026868 — intervention group
Group type: EXPERIMENTAL
Intervention: Cod-based diet
Number of subjects: 276
Study 18026868 — intervention group
Group type: EXPERIMENTAL
Intervention: Seafood-based diets
Number of subjects: 276
Study 18026868 — intervention group
Group type: COMPARATOR
Intervention: Fish-restricted diet (control)
Number of subjects: 276
Study 15539013 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11558044 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar extension exercise (MedX)
Number of subjects: 1100
Study 9432196 — intervention group
Group type: EXPERIMENTAL
Intervention: Made-to-order polysomnograms (single-night sessions)
Number of subjects: 80
Study 9432196 — intervention group
Group type: COMPARATOR
Intervention: Traditional polysomnograms (double-night sessions)
Number of subjects: 80
Study 8418246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diaziquone (AZQ)
Number of subjects: 251
Study 8418246 — intervention group
Group type: COMPARATOR
Intervention: Carmustine (BCNU)
Number of subjects: 251
Study 8418246 — intervention group
Group type: EXPERIMENTAL
Intervention: AZQ with significant hematologic toxicity requiring dose reduction
Number of subjects: 251
Study 8418246 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (45+) and glioblastoma/gliosarcoma (GBM/GS)
Number of subjects: 251
Study 8418246 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age or GBM/GS
Number of subjects: 251
Study 8418246 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (< 45) and non-GBM/GS (usually anaplastic astrocytoma)
Number of subjects: 251
Study 8418246 — intervention group
Group type: COMPARATOR
Intervention: BCNU
Number of subjects: 251
Study 3530138 — intervention group
Group type: EXPERIMENTAL
Intervention: MCOP (mitoxantrone, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 44
Study 3530138 — intervention group
Group type: COMPARATOR
Intervention: CHOP (adriamycin, cyclophosphamide, vincristine, and prednisolone)
Number of subjects: 44
Study 3530138 — intervention group
Group type: EXPERIMENTAL
Intervention: MCOP
Number of subjects: 44
Study 3530138 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 44
Study 3530138 — intervention group
Group type: EXPERIMENTAL
Intervention: MCOP and CHOP
Number of subjects: 44
Study 29131689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 27
Study 26519751 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mirroring (Group II)
Number of subjects: 50
Study 26519751 — intervention group
Group type: COMPARATOR
Intervention: Mirroring of the entire unaffected side (Group I)
Number of subjects: 50
Study 25069621 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based intervention (empirically supported behavior-change strategies, daily skills, self-monitoring text messages with personalized feedback, biweekly counseling calls from a health coach, access to a Facebook support group)
Number of subjects: 18
Study 25069621 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 18
Study 25069621 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-based intervention
Number of subjects: 18
Study 22692758 — intervention group
Group type: EXPERIMENTAL
Intervention: MVA-5T4 (TroVax)
Number of subjects: 0
Study 22692758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20210368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (as a single agent or in combination with chemotherapy)
Number of subjects: 0
Study 20210368 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab added to CHOP chemotherapy
Number of subjects: 0
Study 20210368 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy followed by autologous haematopoietic cell transplant (autoHCT)
Number of subjects: 0
Study 20210368 — intervention group
Group type: EXPERIMENTAL
Intervention: AutoHCT in highly selected individuals up to age 70 years
Number of subjects: 0
Study 20210368 — intervention group
Group type: COMPARATOR
Intervention: Close observation until specific therapeutic indications arise
Number of subjects: 0
Study 18601670 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal soft contact lenses (BSCL)
Number of subjects: 2
Study 18601670 — intervention group
Group type: COMPARATOR
Intervention: Single vision soft contact lenses (SVSCL)
Number of subjects: 2
Study 15980707 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 39
Study 15980707 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 39
Study 12452245 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg before skin incision
Number of subjects: 80
Study 12452245 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg after skin incision
Number of subjects: 80
Study 12452245 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg and ketamine 30 mg before skin incision
Number of subjects: 80
Study 12452245 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 3 mg and ketamine 30 mg after skin incision
Number of subjects: 80
Study 10604407 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene 60 mg/d for 6 months, followed by randomization to continue beta-carotene or placebo for 12 additional months.
Number of subjects: 50
Study 10604407 — intervention group
Group type: COMPARATOR
Intervention: Placebo after initial beta-carotene treatment.
Number of subjects: 50
Study 10604407 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene treatment for 6 months.
Number of subjects: 50
Study 10604407 — intervention group
Group type: COMPARATOR
Intervention: Placebo after beta-carotene treatment.
Number of subjects: 50
Study 7864103 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration (12.5-24 micrograms.kg-1.day-1; n = 8)
Number of subjects: 23
Study 7864103 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 23
Study 1518636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine concentration of 1:200,000
Number of subjects: 0
Study 1518636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine concentration of 1:100,000
Number of subjects: 0
Study 1518636 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 0
Study 1518636 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine concentration of 1:50,000
Number of subjects: 0
Study 6387286 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood cardioplegia
Number of subjects: 90
Study 31511967 — intervention group
Group type: EXPERIMENTAL
Intervention: Path integral approach to generating functions for multistep post-transcription and post-translation processes.
Number of subjects: 6
Study 29112721 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate condition (tailored report received at the well-child visit)
Number of subjects: 0
Study 29112721 — intervention group
Group type: COMPARATOR
Intervention: Delayed condition (tailored report received at the end of the study)
Number of subjects: 0
Study 26320696 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized hybrid ESD
Number of subjects: 70
Study 26320696 — intervention group
Group type: COMPARATOR
Intervention: ESD
Number of subjects: 70
Study 24470003 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (EW)
Number of subjects: 277
Study 24470003 — intervention group
Group type: COMPARATOR
Intervention: Neutral writing (NW)
Number of subjects: 277
Study 23030576 — intervention group
Group type: EXPERIMENTAL
Intervention: Text with symbols format
Number of subjects: 157
Study 23030576 — intervention group
Group type: COMPARATOR
Intervention: Text-only format
Number of subjects: 157
Study 23030576 — intervention group
Group type: COMPARATOR
Intervention: Symbols-only format
Number of subjects: 157
Study 20687838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (1 dose)
Number of subjects: 240
Study 20687838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (2 doses)
Number of subjects: 240
Study 20687838 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 microg AS03A-adjuvanted H1N1 2009 vaccine (1 or 2 doses)
Number of subjects: 240
Study 18487212 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen priming with anastrozole 1 mg on cycle days 2, 3, and 4, hCG 1250 IU, cetrorelix 3 mg on cycle day 2, rFSH 150 IU from cycle day 5
Number of subjects: 103
Study 18487212 — intervention group
Group type: COMPARATOR
Intervention: Control group with flexible antagonist protocol
Number of subjects: 103
Study 18487212 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen priming
Number of subjects: 103
Study 15643540 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite and professional cyclists
Number of subjects: 143
Study 15643540 — intervention group
Group type: EXPERIMENTAL
Intervention: Members of the Italian national cross‐country ski team
Number of subjects: 143
Study 15643540 — intervention group
Group type: COMPARATOR
Intervention: Sedentary healthy controls
Number of subjects: 143
Study 14632733 — intervention group
Group type: EXPERIMENTAL
Intervention: ThinPrep® (TP)
Number of subjects: 120
Study 14632733 — intervention group
Group type: COMPARATOR
Intervention: Conventional smears (CS)
Number of subjects: 120
Study 10228629 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA pre-treatment
Number of subjects: 0
Study 10228629 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin with EMLA
Number of subjects: 0
Study 10228629 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo pre-treatment
Number of subjects: 0
Study 8909454 — intervention group
Group type: EXPERIMENTAL
Intervention: Methazolamide (average dose 168 mg/day)
Number of subjects: 9
Study 8909454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 1985289 — intervention group
Group type: EXPERIMENTAL
Intervention: azathioprine (AZA) 3.0 mg/kg daily
Number of subjects: 59
Study 1985289 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 59
Study 6358645 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcoseryl eye gel
Number of subjects: 92
Study 6358645 — intervention group
Group type: COMPARATOR
Intervention: Control group (neomycin and bacitracin)
Number of subjects: 92
Study 31454328 — intervention group
Group type: EXPERIMENTAL
Intervention: SureFil SDR Flow (SDR)
Number of subjects: 80
Study 31454328 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Flowable Restorative (Filtek Bulk)
Number of subjects: 80
Study 31454328 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z250 XT (Z250)
Number of subjects: 80
Study 31454328 — intervention group
Group type: COMPARATOR
Intervention: Untreated teeth (Control group)
Number of subjects: 80
Study 27924049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day longitudinal NIHSS data
Number of subjects: 0
Study 27924049 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day trajectory subgroup variable
Number of subjects: 0
Study 24576016 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 240
Study 24576016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 25675560 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Neiguan (PC 6) and Jianshi (PC 5) combined with granisetron injection
Number of subjects: 72
Study 25675560 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture at sham-point 1 and sham-point 2
Number of subjects: 72
Study 21917634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding (HFO) for 5 days in LBW subjects
Number of subjects: 20
Study 19890207 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated soda (32 oz daily for 1 week)
Number of subjects: 0
Study 19890207 — intervention group
Group type: COMPARATOR
Intervention: Noncaffeinated soda (32 oz daily for 1 week)
Number of subjects: 0
Study 17302650 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective exercise program (1 hour, twice weekly of walk, strength, balance, and flexibility training)
Number of subjects: 134
Study 17302650 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 134
Study 17302650 — intervention group
Group type: EXPERIMENTAL
Intervention: Collective exercise program
Number of subjects: 134
Study 14693614 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB irradiation
Number of subjects: 8